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CHAPTER 1: PUBLISHED ARTICLE 
ILLNESS EPISODES IN A COHORT OF PRETERM INFANTS IN THEIR FIRST 
YEAR OF LIFE 
Background: There is limited data available regarding the illness episodes and hospital 
admissions of preterm infants after initial discharge in low- and middle-income countries. 
Objectives: To prospectively follow a cohort of HIV unexposed preterm infants (29-34 
weeks) and describe their illness episodes, admissions and associated risk factors over a 
one-year period. 
Methods: The study was nested in a parent study evaluating the efficacy of a monoclonal 
antibody against RSV from Jan 2017 to March 2017. 53 infants were enrolled from two 
government neonatal nurseries in Cape Town, South Africa. Descriptive data were collected 
with regards to perinatal history and socioeconomic factors of the infants’ household.  All 
infants received careful follow-up. Logistic regression was performed to assess association 
between hospitalisation and socio-economic factors. 
Results: All 53 infants who were recruited were followed up over one year.  There were 436 
illness episodes of which 31 were hospital admissions. One infant died at home.  The most 
common illnesses were respiratory (53%) and dermatological (17%) in nature. Lower 
respiratory tract infections accounted for 71% of all hospital admissions.  There were no 
significant associations between socioeconomic subgroups when comparing illness 
episodes or hospital admissions. 
Conclusion:  This is one of the few studies to record all illness episodes and not just 
admissions over a one-year period for HIV unexposed infants. There are high rates of 
intercurrent respiratory infection and hospitalisation of preterm infants in their first year of 
life.  Public health interventions to reduce the risk of LRTI must be strengthened. Larger 
studies need to be done to be able to report on the associations with socioeconomic 
determinants in developing countries. 
Introduction 
Preterm infants account for a large and increasing proportion of neonatal and childhood 
morbidity and mortality worldwide, especially in low and middle income countries (LMIC).1 
Morbidity and mortality in this population is mainly caused by respiratory tract illnesses. 
However, there are limited data available regarding the outcomes of preterm infants after 
discharge in these countries.2,3  
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The aim of this study was to provide a descriptive analysis of the illness episodes and 
hospitilizations of a cohort of preterm infants from two public Neonatal Intensive Care Units 
(NICU’s) in South Africa through one year of follow-up.  
Methods 
This study was nested in a prospective cohort study of preterm infants born between 29- 
and 35-weeks gestational age at Groote Schuur Hospital (GSH) and Mowbray Maternity 
Hospital (MMH) in Cape Town, who were enrolled in a multicenter phase 2b novel 
respiratory syncytical virus (RSV) monoclonal antibody trial.  This double-blinded 
randomised controlled trial (RCT) used a ratio of intervention to placebo of 2:1. Gestational 
age was determined by an ultrasound at less than 20 weeks gestation, or foot length at 
birth.4 
Infants were enrolled following delivery at GSH or MMH neonatal units from 1 January 2017 
to 31 March 2017. Inclusion criteria were healthy infants born between 29 weeks 0 days and 
34 weeks 6 days’ gestational age and maternal informed consent.  Exclusion criteria for the 
parent study were: 
1. If caregivers were unable to follow up or if there was doubt regarding follow-ups. E.g.
extreme poverty, adoption, significant medical or mental illness, opioid drug
addiction or maternal age <18yrs.
2. Maternal HIV infection.
3. Any acute illnesses, blood products or drug therapy two weeks prior to enrollment
(except multivitamins, iron or probiotics).
4. Any known chronic illness, except for children with uncomplicated congenital heart
disease (e.g. patent ductus arteriosus, small septal defect).
The reason for excluding these infants from the parent study was to remove the possible 
confounding effects that they could have had on the assessment of the vaccine. 
All participants from the parent study were eligible for the nested study. Follow up occurred 
at the research center at Red Cross Hospital (RXH) on days 8, 31, 91, 151 and 361 after 
discharge. Clinical and socioeconomic data, feeding choice and any illness, clinic visits or 
hospital admission were obtained at each follow up visit.  Exclusive breast milk was defined 
as no other food or drink, not even water.  The infants’ folders were also reviewed to obtain 
the perinatal data.  Data were collected via a standardised questionnaire completed by the 
study staff at each follow up visit.  The research team was comprised of nurses and doctors. 
To ensure no illnesses were missed the following measures in addition to the routine visits 




• In case of illness, emergencies or any adverse incident, caregivers made telephonic 
contact (available 24hours a day) with the research team. 
• These calls were logged, advice was given, and infants were followed up as either 
in- or outpatients, where further information was collected. 
• Caregivers were phoned on a monthly basis to inquire about any symptoms or 
illnesses. 
All diagnoses were made upon assessment by a doctor and recorded when infants followed 
up as either and in- or out-patients.  This information was used to collect data on illness 
episodes and hospitalisations for the nested study.  
 
The primary outcome for the RSV monoclonal study was medically attended RSV-LRTI.  For 
this nested study the primary outcome was to describe maternal and infant characteristics 
and all infant intercurrent illness episodes through one year after discharge. 
 
Ethical approval for the nested study was granted by the Human Research Ethics 
Committee, Faculty of Health Sciences, University of Cape Town (ref 886/2016). All mothers 




Data were analysed using RStudio version 1.1.463. Continuous variables were summarised 
as medians with interquartile range (IQR) for non-parametric data. Categorical variables 
were expressed as frequencies and percentages.  To assess whether there were 
associations between the socio-economic factors and hospital admissions, a logistic linear 
regression was done.  Gestational age and birth weight were adjusted for in the logistic 




Enrollment and follow-up 
56 infants were enrolled in the RSV monoclonal study from Groote Schuur and Mowbray 
Maternity Hospitals; all were offered participation in the follow-up study of whom three 
declined. The study therefore included 53 preterm infants of which there were four sets of 
twins. No infant was lost to follow-up during the 1-year period, but one infant died at 130 






The median age of the mothers at time of delivery was 28 years with five mothers being less 
than 20 years of age.  Table 1 describes the maternal characteristics   
 
Table 1: Characteristics of mothers (n=49) 
Outcome Median (IQR) Frequency (%) 
Maternal age at time of delivery 28 (23, 32)  
Attended antenatal care  43 (88) 
Booking bloods   
Positive rapid plasma reagin  1 (2) 
Rhesus negative  3 (6) 
Gravidity  1 (1, 2)  
Antenatal treatment   
None  20 (41) 
Steroids  18 (37) 
Magnesium sulphate  6 (12) 
Steroids and Magnesium sulphate  5 (10) 
Maternal illnesses during pregnancy   
Pre eclampsia / Eclampsia  8 (16) 
Sepsis / Infection  7 (14) 
Maternal illnesses known prior to 
pregnancy 
  
Cardiac   2 (4) 
Lung disease  3 (6) 
Endocrine  2 (4) 
Other  4 (8) 
Housing  
Shack 10 (21) 
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Wendy house 4 (8) 
Apartment 8 (16) 
Free standing house 27 (55) 
Access to water  
Piped inside the house 36 (73) 
Piped outside the house 9 (18) 
Communal tap outside the yard 4 (9) 
Level of education of mother  
Grade 0 to 7 4 (8) 
Grade 8 to 12 40 (82) 
Diploma / Degree 5 (10) 
Yearly income of household  
< R 99 999 44 (90) 
R 100 000 to R 350 000 1 (2) 
> R 350 001 4 (8) 
Smoking in the home  
No 33 (67) 
Yes 16 (33) 
Substance abuse in the home*  7 (14) 
 
*Opioids, marijuana and amphetamines 
 
The majority of mothers (35, 71%) were living in formal housing and all mothers had access 
to electricity.  43 mothers (88%) had some high school education and in four (8%) the highest 
level of education was primary school.  The median number of people living in the same 
dwelling, including the infants, was 7 (IQR 5, 8).  Refer to table 1 for maternal medical and 
socio-economic background. 
 






Most infants (35 (66%) were born by emergency Caesarian section with a median birth 
weight of 1500 grams, table 2.  The median length of stay after birth was 27 days. 
 
There were two infants with congenital abnormalities; one infant had upper limb dysgenesis 
and another had a ventricular septal defect (VSD). Three infants were diagnosed with patent 
ductus arteriosis (PDA) via echocardiogram all of which spontaneously closed.   
 
 
Table 2: Infant characteristics (n = 53) 
Outcome Median (IQR) Frequency 
(%) 
 
Mode of delivery   
Caesarian section  35 (66) 
Vaginal delivery  18 (34) 
Length of stay after birth 27 (23, 31)   
Male  32 (60)  
Birth weight (in grams) 1500 (1300, 1840)   
Gestational age at birth (in weeks+days) 32 weeks (30+3, 33+2)   
Head circumference for age at birth 
(Z-score) 
0.04 (-1.07, 0.61)   
Apgar scores    
1 minutes 7 (5, 8)   
5 minutes 9 (8, 10)   
Initial resuscitation required    
None  27 (51)  
Oxygen  1 (2)  





 5 (9)  
Intubation  2 (4)  
Epinephrine  1 (2)  
Surfactant required  2 (4)  
Temperature at admission 36.1 (35.9, 36.4)   
Congenital abnormalities  2 (4)  
Highest level of respiratory support    
Room air  18 (34)  
Nasal prong oxygen  3 (6)  
High flow nasal cannulas  7 (13)  
Nasal CPAP  22 (42)  
Mechanical ventilation  3 (6)  
Feeding at discharge    
Exclusive breast milk (EBM)  50 (94)  
Breast milk substitute  2 (4)  
Mixed  1 (2)  
Twins   4 (8)  
 
 
The number of infants who had fathers that provided financially was 43 (81%) at Day 8 and 
gradually declined to 37 (70%) by Day 361.  Fathers lived in the same dwelling at birth for 
31 (58%) of the infants, with a gradual decline to 27 (51%). Substance misuse (opioids, 
marijuana and amphetamines) fluctuated between 2 and 9% of the households.  
 
At 1 year, only four infants were attending crèche and all the others were cared for by family 
members. 
 
There was a high proportion of infants that received EBM from birth until discharge (50, 
94%) with a gradual reduction over time (Fig. 1).  By day 151, 9 infants (17%) received EBM 
 
8 
and 19 infants (37%) received any breast milk.  By day 361, there were still 19 infants (37%) 
receiving any breast milk. 
 
 
Figure 1: Percentage of infants that received exclusive and any breast milk over one year 
 
Weight for corrected age (median, IQR) Z scores were day 31: -0,58 (-1,52, 0,08); day 91: 
-021 (-0,85, 0,29) and day 151: -0,49 (-1,08, 0,07). One infant had failure to thrive at 4 




By day 361, 91% of infants had received all their vaccines including the 9 months measles 
and pneumococcal vaccines.   
 
 
Intercurrent illness episodes and hospital admissions 
The total number of illness episodes reported over the study period was 436 with a median 
of 7 (IQR 5, 11) illness episodes per infant per year (e/iy).  The most common illness (170, 
39%) was upper respiratory tract infections (URTI) with a rate of 3.2 e/iy. 72 (17%) illness 
episodes were attributed to dermatological conditions with a rate of 1.4 e/iy and 59 (14%) 
illness episodes with a rate of 1.1 e/iy for both LRTI and gastrointestinal disorders. 
 
 
Table 3: Illness episodes in infants through 1 year of age 
Type of illness Total number of illness episodes 
n = 436 (%) 


























Dermatological 72 (17%) 
Napkin dermatitis 12 
Viral exanthem 12 
Other 11 
Falliculitis / Impetigo 9 
Fungal  7 
Scabies 7 
Papular urticuria 7 
Tinea 4 
Mouth ulcers 3 
Gastrointestinal 59 (14%) 
Gastroenteritis 43 
Reflux 5 
Oral thrush 5 
Constipation 2 
Dysentery 2 
Abdominal cramps 2 
Ears, nose and throat 15 (3%) 
Otitis media 13 
Tonsilitis 1 
Laryngomalacia 1 





Ophthalmological 10 (2%) 
Conjunctivitis 7 
Blocked duct 3 




Surgical 9 (2%) 
Burn 2 
Umbilical hernia 2 
Abscess 2 




Cardiac 6 (1%) 
Allergy 5 (1%) 
Eczema 3 
Allergic rhinitis 2 




Urology 3 (1%) 
Malnutrition* 2 (1%) 
 




Over the one-year of follow-up, 20 (38%) infants were admitted to hospital, with a total of 31 
admissions. Of the 31 admissions, 29 were managed medically and two required surgical 
interventions (repair of a VSD and drainage of an abscess). Four required admission to ICU.  
Lower respiratory tract infection accounted for 22 (71%) of all hospital admissions (Fig. 2) 
with a rate of 0.4 e/iy.  The median corrected age of hospital admissions was 12 weeks+3 days 
(IQR 5+2, 28+2) and the median length of hospital stay was 5 days (IQR 3, 7). There was no 




Figure 2:  Reasons for hospital admissions 
 
One infant with presumed pneumonia died at home, giving an overall mortality rate of 1 in 
53 (2%); no postmortem was permitted.  
 
 















Reasons for hospital admissions
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Table 4 shows the multivariate logistic regression of factors associated with hospital 
admission.  One infant with a VSD had a large number of illness episodes and hospital 
admissions unrelated to prematurity, so this infant was excluded from the multivariate 
analysis.  Gestation age and birth weight were adjusted for as these are known confounders 
to the outcomes in this population group.  None of the variables showed statistically 
significant associations.    
 
 
Table 4:  Multivariate logistic regression of the association between hospital admission and 
socio-economic factors, adjusted for gestational age and birth weight 
Variable Estimated OR (95% CI) p-value 
Smoking in the home    
Yes 1.0  
No 2.760 (0.773 - 11.703) 0.135 
Maternal drug abuse during pregnancy   
Yes 1.0  
No 1.624 (0.275 - 9.300) 0.575 
Drug abuse in the home   
Yes 1.0  
No 1.52 (0.16 - 33.26) 0.73 
Number of people sleeping in the same 
dwelling 
0.94 (0.70 - 1.23)  0.64 
Father living in the same dwelling at Day 
361 
  
Yes 1.0  
No 0.63 (0.19 - 2.07) 0.45 
Father providing support at Day 361   
Yes 1.0  
No 1.90 (0.53 - 6.81) 0.32 
Feeding at Day 31   
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Breast milk 1.0  
Any breast milk 0.60 (0.16 - 2.07) 0.42 
Breast milk substitutes 2.90 (0.38 - 29.67) 0.32 
Housing   
Shack 1.0  
Wendy house 0.55 (0.02 - 6.32) 0.65 
Apartment 0.31 (0.01 - 3.13) 0.37 
Freestanding house 1.21 (0.29 - 5.56) 0.80 
Access to water   
Piped inside dwelling 1.0  
Piped inside the yard 1.77 (0.37 - 8.44) 0.46 
Communal tap 1.36 (0.15 - 10.15) 0.76 
Immunisation up to date at Day 361   
Yes 1.0  
No 1.14 (0.28 - 4.30) 0.85 
 




This study has shown a high prevalence of poor socioeconomic factors and smoke exposure 
as well as a high number of hospitalisations in this group of South African preterm infants, 
but low mortality. There were no associations between hospital admissions and 
socioeconomic factors, but this may partly be due to the relatively poor socioeconomic status 
of all participants with no participants from high socioeconomic groups. Further, the small 
sample size limits the power of the analyses to detect such associations.   
 
Due to the rigorous follow-up, this is one of the few studies to accurately record all illness 
episodes and not just admissions to hospital. Respiratory tract infections (URTI and LRTI) 
contributed just over half of all illness episodes. Of the 229 respiratory tract infections 




More than a third of infants were admitted to hospital over the one-year follow-up.  These 
results are higher than those from a systematic review6, in which 25% of low or very low 
birth weight infants required hospitalisation in the first year of life, however the studies 
included in the systematic review were done in high income countries.  The reason for the 
higher rate of hospital admissions in this population could be due to a higher burden of 
infectious diseases in LMICs and higher exposure to risk factors.  This is especially true for 
severe LRTIs as a major cause of hospitalisation, which is consistent with studies from other 
settings.7,8 The high burden of respiratory conditions highlights the need to strengthen 
preventative interventions and new strategies to tackle this burden on the health sector.   
 
Environmental exposures that may be associated with LRTI include smoke exposure.9–11 Of 
concern is that a third of infants (33%) in this study were exposed to household smoke.  
Crowding may be another factor; the household size in this study was higher than the 4.9 
mean household size for people living with children in South Africa in 201812. Lack of 
breastfeeding may be an additional risk factor.  Despite the WHO recommendations for EBM 
until six months of age, this study again demonstrates the low rates of EBM in South Africa.  
By day 151 only 9 (17%) of the infants received EBM which is similar to another local study 
where only 12% received EBM.13,14 Encouragingly, most of the infants were transitioned to 
solid feeds after 6 months.  In a Lancet systematic review from 2016, it was found that 
breastfeeding reduced diarrhoea episodes by approximately 50% and further reduced 
hospital admissions for diarrhoea by 72%.  Breastfeeding also reduced 33% of respiratory 
infections and 57% of hospital admissions due to respiratory infections.15 Even though 
exclusive breastfeeding is the ideal, any breastfeeding should be encouraged as there is a 
modest protective dose response effect with partial breastfeeding when compared to 
nonbreastfeeding.16 
 
Lack of immunisations make a child more vulnerable to LRTI and preterm infants should be 
vaccinated according to their chronological and not corrected age.17 Only  9% of infants in 
this study were not up to date with their vaccines, which  is lower than the average of 19% 
of infants with incomplete vaccination reported in the Western Cape province.14   
 
Poor levels of parental education have shown to be associated with worse outcomes and 
an increased risk for preterm infant mortality.18 Only six of the infants’ mothers in this study 
had a form of post school qualification.  There was however a low mortality rate of 2% in this 
study. In contrast, a study in 1997, following very low birth weight (VLBW) infants in South 
Africa over eighteen months, reported a 13% mortality rate.19 The lower mortality rate in this 
study may reflect improvements in care due to advances in technology and maternal and 
infant management. Further, the high coverage of childhood immunisations, exclusion of 
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HIV-infected mothers and regular follow-up through the study may all have contributed to 
improved outcomes.   
 
No association was shown for infant morbidity in those families where substance abuse was 
reported, however there may have been under reporting due to the fluctuating reported 
numbers and the prevalence being well below the nation average of 13%.20 
 
It is surprising that in such a closely monitored group two infants developed severe 
malnutrition, but this highlights the constant threat of food security in many of our 
communities.  
 
Due to the nature of the infants included in the parent study this sample was expected to be 
healthier than the ones excluded.  It is therefore assumed that the true results of the general 
population could be even worse.  
 
 
Strengths and limitations 
A strength of the study is the comprehensive follow-up and the ability to identify all 
intercurrent illness episodes and not only hospital admissions over a year for each infant. 
 
This study was nested in a much larger funded study and whilst this resulted in excellent 
follow-up, there are three important limitations which hinder the generalization of the results. 
 
The first limitation is that all babies were HIV unexposed (HU). It has been shown that HIV 
exposed uninfected (HEU) infants have an increased infectious morbidity when compared 
to HU infants.21 There has been debate that many of the earlier studies were done before 
the move to early universal maternal ART and exclusive breastfeeding which may 
ameliorate some of the mechanisms responsible for these earlier findings.  Le Roux et al22 
showed that even with maternal ART and universal breastfeeding (HEU) infants have an 
increased incidence rate ratio of infection-related hospitalisations when compared to HU 
infants but this was significant only in the first three months of life. 
 
Although the efficacy of the monoclonal antibody in the parent study is still unknown (results 
have not yet been published) it is possible that those infants who received the antibody 
would have been less likely to consult or be admitted for complications of RSV. Other RSV 
monoclonal antibodies such as palivizumab and motavizumab have been shown to 





Finally, the ‘most as risk infants’ could have been excluded due to inclusion criteria ruling 
out mothers who were unlikely to come to follow-up visits.  Linked to this is that because 
participants were part of a study follow-up and had access to care, the outcomes could differ 
from those patients without such access. 
 
Despite these limitations, this study remains important as it shows not only hospital 
admissions but also the high number of illness episodes in this cohort of preterm infants. It 
is probably that these results are an under-representation of what could be anticipated in 
the general population, especially if the higher risk infants are included and monoclonal 
antibodies are not available. 
 
Conclusion 
There are high rates of intercurrent infection and hospitalisation in HU preterm infants in 
their first year of life.  Public health interventions to reduce the risk of LRTI must be 
strengthened, including promoting exclusive breastfeeding, avoidance of tobacco smoke 
exposure and improvements in living conditions.  Larger studies are needed to investigate 
the association between various socioeconomic determinants and intercurrent illnesses in 
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TITLE OF STUDY: The outcome of well preterm infants (29-35 weeks) admitted to 
two Neonatal Intensive Care Units in state institutions in Cape Town followed up 






You are already involved in a study where you may be receiving medication to prevent 
lung infections in your preterm baby. This study is called: 
A Phase 2b Randomized, Double-blind, Placebo-controlled Study to Evaluate the 
Safety and Efficacy of MEDI8897, a Monoclonal Antibody with an Extended Half-life 
Against Respiratory Syncytial Virus, in Healthy Preterm Infants 
 
We want to do an additional study to try and understand more about what happens to 
our premature babies. During the study you have already signed for, your baby will be 
followed-up five times during the next year. We would like to ask you an additional set 
of questions at each follow up. These questions will mainly be about your living 
conditions and your baby’s health. We will also weigh, measure the length and head 
size of your baby at each follow up. There will be no additional samples taken or 
procedures done for this study. 
 
There are no risks to participating in this study and you may at any time withdraw from 
this study and anonymity will be respected always. No compensation will be offered 
for participation in the study but the study may help other babies in the future by helping 
our understanding of the management. 
 
Should any participant have any further queries concerning this study, the investigator 
can be contacted: 
Seth Muller 
Telephone number: 021 658 5111 
Email: mullerseth@gmail.com 
 



























Date of birth dd mm cccc 
Date of initial discharge dd mm cccc 
 
Gender Male Female 
 
Birth weight g 
 
Gestational age Weeks Days 
 
Head circumference at birth cm 
 
Length at birth cm 
 










Surfactant required Yes No 
 
Temperature within first hour of admission Degrees 
 
Congenital abnormalities Yes No 




Left: IVH 1 IVH 2 IVH 3 IVH 4 
Right: IVH 1 IVH 2 IVH 3 IVH 4 
PVL Not done 
 
Highest level of respiratory support during 
initial admission 
 














Neonatal sepsis Yes No 
 
Oxygen required at 36 weeks gestational age Yes No 
 
HIV Birth PCR Not applicable Negative Positive 
 







Household income H0 H1 H2 H3 P 
 
Maternal age at delivery Years 
 
Pre-natal care Booked Unbooked 
 
Booking bloods 
RPR Rhesus HIV 




Maternal hypertension None Chronic Pregnancy- induced 
 
Antenatal treatment None Steroids MgSO4 
 
Maternal illnesses None Diabetes Other 
 
If other, elaborate 
 
 
Maternal substance abuse Yes No 
If yes, elaborate  
 
Mode of delivery NVD Forceps Vacuum Caesarian section 
 
Prolonged rupture of membrane Yes No 










Infant address  
 
Race African Coloured Caucasian Indian Asian 
 




Number of people living in same dwelling  
 
Drug abuse in the same dwelling Yes No 
 
Primary caregiver  
 
Father living in the same dwelling Yes No 
 
Father providing financial support Yes No 
 
Person looking after infant for most the day  
 
Travel outside of Western Province Yes No 
If yes, elaborate  
 




Feeding choice Breast milk Formula Mixed 
 
Introduction to solid food initiated Yes No 
If yes, when?  
 
KMC at present Yes No 
Research nr 









Any hospital admissions from the last visit Yes No 
If yes, where  
If yes, why  
 
Immunisation: 
Birth BCG Yes No 
OPV (1) Yes No 
Six weeks OPV (2) Yes No 
RV (1) Yes No 
DTaPIPV / HiB (1) Yes No 
HepB (1) Yes No 
PCV 13 (1) Yes No 
Ten weeks DTaPIPV / HiB (2) Yes No 
HepB (2) Yes No 
Fourteen weeks RV (2) Yes No 
DTaPIPV / HiB (3) Yes No 
HepB (3) Yes No 
PCV 13 (2) Yes No 
Six months Measles Vaccine (1) Yes No 
Nine months PCV 13 (3) Yes No 
Twelve months Measles Vaccine (2) Yes No 










Infant address  
 











Access to electricity in dwelling Yes No 
 






Number of people living in same dwelling  
 
Smokers living in same dwelling Yes No 
 
Drug abuse in the same dwelling Yes No 
 
Primary caregiver  
 
Father living in the same dwelling Yes No 
 
Father providing financial support Yes No 
 




Attending crèche Yes No 
 
Travel outside of Western Province Yes No 
If yes, elaborate  
 




Feeding choice Breast milk Formula Mixed 
 
Introduction to solid food initiated Yes No 
If yes, when?  
 
KMC at present Yes No 
Research nr 










Any hospital admissions from the last visit Yes No 
If yes, where  
If yes, why  
 
Immunisation: 
Birth BCG Yes No 
OPV (1) Yes No 
Six weeks OPV (2) Yes No 
RV (1) Yes No 
DTaPIPV / HiB (1) Yes No 
HepB (1) Yes No 
PCV 13 (1) Yes No 
Ten weeks DTaPIPV / HiB (2) Yes No 
HepB (2) Yes No 
Fourteen weeks RV (2) Yes No 
DTaPIPV / HiB (3) Yes No 
HepB (3) Yes No 
PCV 13 (2) Yes No 
Six months Measles Vaccine (1) Yes No 
Nine months PCV 13 (3) Yes No 
Twelve months Measles Vaccine (2) Yes No 











Number of people living in same dwelling  
 
Drug abuse in the same dwelling Yes No 
 
Father living in the same dwelling Yes No 
 
Father providing financial support Yes No 
 




Attending crèche Yes No 
 
Travel outside of Western Province Yes No 
If yes, elaborate  
 
Feeding choice Breast milk Formula Mixed 
 
Introduction to solid food initiated Yes No 
If yes, when?  
 
KMC at present Yes No 
 
Developmental milestones Date 
Rolling  
Neck control  
Sitting without support  
Crawling  
Standing with assistance  
Standing alone  
Walking with assistance  








Any hospital admissions from the last visit Yes No 
If yes, where  
Research nr 
Patient details / Patient sticker 
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If yes, why  
 
Immunisation: 
Birth BCG Yes No 
OPV (1) Yes No 
Six weeks OPV (2) Yes No 
RV (1) Yes No 
DTaPIPV / HiB (1) Yes No 
HepB (1) Yes No 
PCV 13 (1) Yes No 
Ten weeks DTaPIPV / HiB (2) Yes No 
HepB (2) Yes No 
Fourteen weeks RV (2) Yes No 
DTaPIPV / HiB (3) Yes No 
HepB (3) Yes No 
PCV 13 (2) Yes No 
Six months Measles Vaccine (1) Yes No 
Nine months PCV 13 (3) Yes No 
Twelve months Measles Vaccine (2) Yes No 











Number of people living in same dwelling  
 
Smokers living in same dwelling Yes No 
 
Drug abuse in the same dwelling Yes No 
 
Primary caregiver  
 
Father living in the same dwelling Yes No 
 
Father providing financial support Yes No 
 
Person looking after infant for most the day  
 
Attending crèche Yes No 
 
Travel outside of Western Province Yes No 
If yes, elaborate  
 




Feeding choice Breast milk Formula Mixed 
 
Introduction to solid food initiated Yes No 
If yes, when?  
 
KMC at present Yes No 
Research nr 
Patient details / Patient sticker 
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Developmental milestones Date 
Rolling  
Neck control  
Sitting without support  
Crawling  
Standing with assistance  
Standing alone  
Walking with assistance  








Any hospital admissions from the last visit Yes No 
If yes, where  
If yes, why  
 
Immunisation: 
Birth BCG Yes No 
OPV (1) Yes No 
Six weeks OPV (2) Yes No 
RV (1) Yes No 
DTaPIPV / HiB (1) Yes No 
HepB (1) Yes No 
PCV 13 (1) Yes No 
Ten weeks DTaPIPV / HiB (2) Yes No 
HepB (2) Yes No 
Fourteen weeks RV (2) Yes No 
DTaPIPV / HiB (3) Yes No 
HepB (3) Yes No 
PCV 13 (2) Yes No 
Six months Measles Vaccine (1) Yes No 
Nine months PCV 13 (3) Yes No 
Twelve months Measles Vaccine (2) Yes No 










Infant address  
 
Number of people living in same dwelling  
 
Drug abuse in the same dwelling Yes No 
 
Primary caregiver  
 
Father living in the same dwelling Yes No 
 
Father providing financial support Yes No 
 
Person looking after infant for most the day  
 
Attending crèche Yes No 
 
Travel outside of Western Province Yes No 
If yes, elaborate  
 




Feeding choice at present Breast milk Formula Mixed 
 
Introduction to solid food initiated Yes No 
If yes, when?  
 
KMC at present Yes No 
Research nr 
Patient details / Patient sticker 
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Any hospital admissions from the last visit Yes No 
If yes, where  
If yes, why  
 
Developmental milestones Date 
Rolling  
Neck control  
Sitting without support  
Crawling  
Standing with assistance  
Standing alone  
Walking with assistance  









Birth BCG Yes No 
OPV (1) Yes No 
Six weeks OPV (2) Yes No 
RV (1) Yes No 
DTaPIPV / HiB (1) Yes No 
HepB (1) Yes No 
PCV 13 (1) Yes No 
Ten weeks DTaPIPV / HiB (2) Yes No 
HepB (2) Yes No 
Fourteen weeks RV (2) Yes No 
DTaPIPV / HiB (3) Yes No 
HepB (3) Yes No 
PCV 13 (2) Yes No 
Six months Measles Vaccine (1) Yes No 
Nine months PCV 13 (3) Yes No 
Twelve months Measles Vaccine (2) Yes No 
Eighteen months DTaPIPV / HiB (4) Yes No 
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To submit a manuscript, please proceed to the SAJCH Editorial Manager 
website: Editorial Manager 
 
 





Please take the time to familiarise yourself with the policies and processes below. If 
you still have any questions, please do not hesitate to ask our editorial staff (tel.: +27 
(0)21 532 1281, email: submissions@hmpg.co.za). 
 
 
Article Processing Charges 
All articles published in the South African Journal of Child Health are open access and 
freely available online upon publication. This is made possible by applying a business 
model to offset the costs of peer review management, copyediting, design and 
production, by charging an article-processing charge (APC) of R3 180 (ex Vat) for all 
articles published. The charge applies only to Research articles submitted after 1 Jan 




When submitting a Research article to the SAJCH, the submitting author must agree 
to pay the APC should the article be accepted for publication. The APC is payable 
when your manuscript is editorially accepted and before production commences for 
publication. The submitting author will be notified that payment is due and given details 
on the available methods of payment. Prompt payment is advised; the article will not 
enter into production until payment is received. 
Queries can be directed to claudian@hmpg.co.za. 
Please refer to the section on ‘Sponsored Supplements’ regarding the publication of 
supplements, where a charge is applicable. Queries can be directed to 






Named authors must consent to publication. Authorship should be based on: (I) 
substantial contribution to conceptualisation, design, analysis and interpretation of 
data; (II) drafting or critical revision of important scientific content; or (III) approval of 
the version to be published. These conditions must all be met for an individual to be 
included as an author (uniform requirements for manuscripts submitted to biomedical 
journals; refer to www.icmje.org) 
 
 
If authors’ names are added or deleted after submission of an article, or the order of 
the names is changed, all authors must agree to this in writing. 
 
 
Please note that co-authors will be requested to verify their contribution upon 
submission. Non-verification may lead to delays in the processing of submissions. 
Author contributions should be listed/described in the manuscript. 
 
 
Conflicts of interest 
Conflicts of interest can derive from any kind of relationship or association that may 
influence authors’ or reviewers’ opinions about the subject matter of a paper. The 
existence of a conflict – whether actual, perceived or potential – does not preclude 
publication of an article. However, we aim to ensure that, in such cases, readers have 
all the information they need to enable them to make an informed assessment about 
a publication’s message and conclusions. We require that both authors and reviewers 
declare all sources of support for their research, any personal or financial relationships 
(including honoraria, speaking fees, gifts received, etc) with relevant individuals or 
organisations connected to the topic of the paper, and any association with a product 
or subject that may constitute a real, perceived or potential conflict of interest. If you 
are unsure whether a specific relationship constitutes a conflict, please contact the 
editorial team for advice. If a conflict remains undisclosed and is later brought to the 
attention of the editorial team, it will be considered a serious issue prompting an 
investigation with the possibility of retraction. 
 
 
Research ethics committee approval 
Authors must provide evidence of Research Ethics Committee approval of the 
research where relevant. Ensure the correct, full ethics committee name and reference 
number is included in the manuscript. 
If the study was carried out using data from provincial healthcare facilities, or required 
active data collection through facility visits or staff interviews, approval should be 
sought from the relevant provincial authorities. For South African authors, please refer 
to the guidelines for submission to the National Health Research Database. Research 
involving human subjects must be conducted according to the principles outlined in the 
Declaration of Helsinki. Please refer to the National Department of Health’s guideline 
on Ethics in Health research: principles, processes and structures to ensure that the 
appropriate requirements for conducting research have been met, and that the 





Since 1st December 2005, all clinical trials conducted in South Africa have been 
required to be registered in the South  African  National  Clinical  Trials  Register.  The 
SAJCH therefore requires that clinical trials be registered in the relevant public trials 
registry at or before the time of first patient enrollment as a condition for publication. 
The trial registry name and registration number must be included in the manuscript. 
Protection of rights to privacy 
 
Patient 
Information that would enable identification of individual patients should not be 
published in written descriptions, photographs, radiographs and pedigrees unless the 
information is essential for scientific purposes and the patient (or parent or guardian) 
has given informed written consent for publication and distribution. We further 
recommend that the published article is disseminated not only to the involved 
researchers but also to the patients/participants from whom the data was drawn. Refer 
to Protection of Research Participants. The signed consent form should be submitted 




Any individual who is identifiable in an image must provide written agreement that the 




Copyright remains in the Author’s name. The work is licensed under a Creative 
Commons Attribution - Noncommercial Works License. Authors are required to 
complete and sign an Author Agreement form that outlines Author and Publisher rights 
and terms of publication. The Agreement form should be uploaded along with other 




Material submitted for publication in the SAJCH is accepted provided it has not been 
published or submitted for publication elsewhere. Please inform the editorial team if 
the main findings of your paper have been presented at a conference and published in 
abstract form, to avoid copyright infringement. The SAJCH does not hold itself 
responsible for statements made by the authors. The corresponding author should also 
indicate if the research forms part of a postgraduate short report, dissertation or thesis. 
 
Previously published images 
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If an image/figure has been previously published, permission to reproduce or alter it 
must be obtained by the authors from the original publisher and the figure legend must 
give full credit to the original source. This credit should be accompanied by a letter 
indicating that permission to reproduce the image has been granted to the author/s. 




The SAJCH is committed to protecting the privacy of its website and submission system 
users. The names, personal particulars and email addresses entered in the website or 
submission system will not be made available to any third party without the user’s 
permission or due process. By registering to use the website or submission system, 
users consent to receive communication from the SAJCH or its publisher HMPG on 
matters relating to the journal or associated publications. Queries with regard to privacy 




Use of racial or ethnicity classifications in research is fraught with problems. If you 
choose to use a research design that involves classification of participants based on 
race or ethnicity, or discuss issues with reference to such classifications, please ensure 
that you include a detailed rationale for doing so, ensure that the categories you 
describe are carefully defined, and that socioeconomic, cultural and lifestyle variables 
that may underlie perceived racial disparities are appropriately controlled for. Please 
also clearly specify whether race or ethnicity is classified as reported by the patient 
(self-identifying) or as perceived by the investigators. Please note thatit is not 




Continuing Professional Development (CPD) 
SAJCH is an HPCSA-accredited service provider of CPD materials. Principal authors 
can earn up to 15 CPD continuing education units (CEUs) for publishing an article; co- 
authors are eligible to earn up to 5 CEUs; and reviewers of articles can earn 3 CEUs. 
Each month, SAJCH also publishes a CPD-accredited questionnaire relating to the 
academic content of the journal. Successful completion of the questionnaire with a 
pass rate of 70% will earn the reader 3 CEUs. Administration of our CPD programme 
is managed by Medical Practice Consulting. To complete questionnaires and obtain 




Preparing an article for anonymous review 
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To ensure a fair and unbiased review process, all submissions are to include an 
anonymised version of the manuscript. The exceptions to this requirement are 
Editorials, Correspondence, Book reviews and Obituary submissions. 
 
 
Submitting a manuscript that needs additional blinding can slow down your review 
process, so please be sure to follow these simple guidelines as much as possible: 
An anonymous version should not contain any author, affiliation or particular 
institutional details that will enable identification. 
Please remove title page, acknowledgements, contact details, funding grants to a 
named person, and any running headers of author names. 
Mask self-citations by referring to your own work in third person. 
 
 
General article format/layout 
Submitted manuscripts that are not in the correct format specified in these guidelines 
will be returned to the author(s) for correction prior to being sent for review, which will 
delay publication. 
General: 
Manuscripts must be written in UK English (this includes spelling). 
The manuscript must be in Microsoft Word or RTF document format. Text must be 1.5 
line spaced, in 12-point Times New Roman font, and contain no unnecessary 
formatting (such as text in boxes). Pages and lines should be numbered consecutively. 
Please make your article concise, even if it is below the word limit. 
Qualifications, FULL affiliation (department, school/faculty, institution, city, country) 
and contact details of ALL authors must be provided in the manuscript and in the online 
submission process. 
Abbreviations should be spelt out when first used and thereafter used consistently, e.g. 
'intravenous (IV)' or 'Department of Health (DoH)'. 
Scientific measurements must be expressed in SI units except: blood pressure 
(mmHg) and haemoglobin (g/dL). 
Litres is denoted with an uppercase L e.g. 'mL' for millilitres). 
Units should be preceded by a space (except for % and ºC), e.g. '40 kg' and '20 cm' 
but '50%' and '19ºC'. 
Please be sure to insert proper symbols e.g. µ not u for micro, a not a for alpha, b not 
B for beta, etc. 
Numbers should be written as grouped per thousand-units, i.e. 4 000, 22 160. 
Quotes should be placed in single quotation marks: i.e. The respondent stated: '...' 
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Round brackets (parentheses) should be used, as opposed to square brackets, which 
are reserved for denoting concentrations or insertions in direct quotes. 
If you wish material to be in a box, simply indicate this in the text. You may use the 




SAJCH is a Journal on child health, therefore for articles involving genetics, it is the 
responsibility of authors to apply the following: 
- Please ensure that all genes are in italics, and proteins/enzymes/hormones are not. 
- Ensure that all genes are presented in the correct case e.g. TP53 not Tp53. 
** NB: Copyeditors cannot be expected to pick up and correct errors wrt the above, 
although they will raise queries where concerned. 
- Define all genes, proteins and related shorthand terms at first mention, e.g. ‘188del11’ 
can be glossed as ‘an 11 bp deletion at nucleotide 188.’ 
- Use the latest approved gene or protein symbol as appropriate: 
Human Gene Mapping Workshop (HGMW): genetic notations and symbols 
HUGO Gene Nomenclature Committee: approved gene symbols and nomenclature 
OMIM: Online Mendelian Inheritance in Man (MIM) nomenclature and instructions 
Bennet et al. Standardized human pedigree nomenclature: Update and assessment of 
the recommendations of the National Society of Genetic Counselors. J Genet Counsel 
2008;17:424-433: standard human pedigree nomenclature. 
 
 




GUIDELINE WORD LIMIT: 3 000 WORDS (EXCLUDING ABSTRACT AND 
BIBLIOGRAPHY) 
 
Research articles describe the background, methods, results and conclusions of an 
original research study. The article should contain the following sections: introduction, 
methods, results, discussion and conclusion, and should include a structured abstract 
(see below). The introduction should be concise – no more than three paragraphs – 
on the background to the research question, and must include references to other 
relevant published studies that clearly lay out the rationale for conducting the study. 
Some common reasons for conducting a study are: to fill a gap in the literature, a 
logical extension of previous work, or to answer an important clinical question. If other 
papers related to the same study have been published previously, please make sure 
to refer to them specifically. Describe the study methods in as much detail as possible 
so that others would be able to replicate the study should they need to. Where 
appropriate, sample size calculations should be included to demonstrate that the study 
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is not underpowered. Results should describe the study sample as well as the findings 
from the study itself, but all interpretation of findings must be kept in the discussion 
section, which should consider primary outcomes first before any secondary or tertiary 
findings or post-hoc analyses. The conclusion should briefly summarise the main 
message of the paper and provide recommendations for further study. 
May include up to 6 illustrations or tables. 




This should be no more than 250words, with the following recommended headings: 
Background: why the study is being done and how it relates to other published work. 
Objectives: what the study intends to find out 
Methods: must include study design, number of participants, description of the 
intervention, primary and secondary outcomes, any specific analyses that were done 
on the data. 
Results: first sentence must be brief population and sample description; outline the 
results according to the methods described. Primary outcomes must be described first, 
even if they are not the most significant findings of the study. 
Conclusion: must be supported by the data, include recommendations for further 
study/actions. 
Please ensure that the structured abstract is complete, accurate and clear and has 
been approved by all authors. It should be able to be intelligible to the reader without 
referral to the main body of the article. 
Do not include any references in the abstracts. 
 
 




SCIENTIFIC LETTERS/short reports 
 
 




GUIDELINE WORD LIMIT: 1500 WORDS 
 
Abstract: unstructured, of about 100-150 words 
May include only one illustration or table 
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GUIDELINE WORD LIMIT: 1 000 WORDS 
 
These opinion or comment articles are usually commissioned but we are happy to 
consider and peer review unsolicited editorials. Editorials should be accessible and 
interesting to readers without specialist knowledge of the subject under discussion and 
should have an element of topicality (why is a comment on this issue relevant now?) 
There should be a clear message to the piece, supported by evidence. 
Please make clear the type of evidence that supports each key statement, e.g.: 
expert opinion 







Review articlesshould always be discussed with the Editor prior to submission. 
 
 
GUIDELINE WORD LIMIT: 4 000 WORDS 
 
 
These are welcome, but should be either commissioned or discussed with the Editor 
before submission. A review article should provide a clear, up-to-date account of the 
topic and be aimed at non-specialist hospital doctors and general practitioners. They 
should be aligned to practice in South and/or sub-Saharan Africa and not a precis of 
reviews published in the international literature 
Please ensure that your article includes: 
Abstract: unstructured, of about 100-150 words, explaining the review and why it is 
important 
Methods: Outline the sources and selection methods, including search strategy and 
keywords used for identifying references from online bibliographic databases. Discuss 
the quality of evidence. 
When writing: clarify the evidence you used for key statements and the strength of the 
evidence. Do not present statements or opinions without such evidence, or if you have 
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to, say that there is little or no evidence and that this is opinion. Avoid specialist jargon 
and abbreviations, and provide advice specific to southern Africa. 
Personal details: Please supply your qualifications, position and affiliations and MP 
number (used for CPD points); address, telephone number and fax number, and your 
e-mail address; and a short personal profile (50 words) and a few words about your 





Correspondence (Letters to the Editor) 
GUIDELINE WORD LIMIT: 400 WORDS 
 
Letters to the editor should relate either to a paper or article published by the SAJCH 
or to a topical issue of particular relevance to the journal’s readership 
May include only one illustration or table 
Must include a correspondence address. 
 
Obituaries 
GUIDELINE WORD LIMIT: 400 WORDS 
 
Should be offered within the first year of the practitioner’s death, and may be 




If illustrations submitted have been published elsewhere, the author(s) should provide 
evidence of consent to republication obtained from the copyright holder. 
Figures must be numbered in Arabic numerals and referred to in the text e.g. '(Fig. 1)'. 
Each figure must have a caption/legend: Fig. 1. Description (any abbreviations in full). 
All images must be of high enough resolution/quality for print. 
All illustrations (graphs, diagrams, charts, etc.) must be in PDF form. 
Ensure all graph axes are labelled appropriately, with a heading/description and units 
(as necessary) indicated. Do not include decimal places if not necessary e.g. 0; 1.0; 
2.0; 3.0; 4.0 etc. 
Scans/photos showing a specific feature e.g. INTERMEDIATE MAGNIFICATION 
MICROGRAPH OF A LOW MALIGNANT POTENTIAL (LMP) MUCINOUS OVARIAN 
TUMOUR. (H&E STAIN). –include an arrow to show the tumour. 
Each image must be attached individually as a 'supplementary file' upon submission 





Tables should be constructed carefully and simply for intelligible data representation. 
Unnecessarily complicated tables are strongly discouraged. 
Large tables will generally not be accepted for publication in their entirety. Please 
consider shortening and using the text to highlight specific important sections, or offer 
a large table as an addendum to the publication, but available in full on request from 
the author. 
Embed/include each table in the manuscript Word file - do not provide separately as 
supplementary files. 
Number each table in Arabic numerals (Table 1, Table 2, etc.) consecutively as they 
are referred to in the text. 
Tables must be cell-based (i.e. not constructed with text boxes or tabs) and editable. 
Ensure each table has a concise title and column headings, and include units where 
necessary. 
Footnotes must be indicated with consecutive use of the following symbols: * † ‡ § ¶ 
|| then ** †† ‡‡ etc. 
 
 





Each row of data must have its own proper row: 
 
 





Combine into one column, N (%): 
 
 











NB: Only complete, correctly formatted reference lists in Vancouver style will be 
accepted. If reference manager software is used, the reference list and citationS IN 
TEXT ARE TO BE UNFORMATTED TO PLAIN TEXT BEFORE SUBMITTING.. 
 
Authors must verify references from original sources. 
Citations should be inserted in the text as superscript numbers between square 
brackets, e.g. These regulations are endorsed by the World Health Organization,[2] and 
others.[3,4-6] 
All references should be listed at the end of the article in numerical order of appearance 
in the Vancouver style (not alphabetical order). 
Approved abbreviations of journal titles must be used; see the List of Journals in Index 
Medicus. 
Names and initials of all authors should be given; if there are more than six authors, 
the first three names should be given followed by et al. 
Volume and issue numbers should be given. 
First and last page, in full, should be given e.g.: 1215-1217 not 1215-17. 
Wherever possible, references must be accompanied by a digital object identifier (DOI) 
link). Authors are encouraged to use the DOI lookup service offered by CrossRef: 
On the Crossref homepage, paste the article title into the ‘Metadata search’ box. 
Look for the correct, matching article in the list of results. 
Click Actions > Cite 
Alongside 'url =' copy the URL between { }. 





JOURNAL REFERENCES: Price NC, Jacobs NN, Roberts DA, et al. Importance of 
asking about glaucoma. Stat Med 1998;289(1):350-355. 
http://dx/doi.org/10.1000/hgjr.182 
BOOK REFERENCES: Jeffcoate N. Principles of Gynaecology. 4th ed. London: 
Butterworth, 1975:96-101. 
CHAPTER/SECTION IN A BOOK: Weinstein L, Swartz MN. Pathogenic Properties of 
Invading Microorganisms. In: Sodeman WA, Sodeman WA, eds. Pathologic 
Physiology: Mechanisms of Disease. Philadelphia: WB Saunders, 1974:457-472. 
INTERNET REFERENCES: World Health Organization. The World Health Report 2002 
- Reducing Risks, Promoting Healthy Life. Geneva: WHO, 2002. 





National Department of Health, South Africa. National Policy for Health Act, 1990 (Act 
No. 116 of 1990). Free primary health care services. Government Gazette No. 
17507:1514. 1996. 
In this example, 17507 is the Gazette Number. This is followed by :1514 - this is the 
notice number in this Gazette. 
Provincial Gazettes: 
Gauteng Province, South Africa; Department of Agriculture, Conservation, 
Environment and Land Affairs. Publication of the Gauteng health care waste 
management draft regulations. Gauteng Provincial Gazette No. 373:3003, 2003. 
Acts: 
South Africa. National Health Act No. 61 of 2003. 
Regulations to an Act: 
South Africa. National Health Act of 2003. Regulations: Rendering of clinical forensic 
medicine services. Government Gazette No. 35099, 2012. (Published under 
Government Notice R176). 
Bills: 
South Africa. Traditional Health Practitioners Bill, No. B66B-2003, 2006. 
Green/white papers: 
South Africa. Department of Health Green Paper: National Health Insurance in South 
Africa. 2011. 
Case law: 
Rex v Jopp and Another 1949 (4) SA 11 (N) 
Rex v Jopp and Another: Name of the parties concerned 
1949: Date of decision (or when the case was heard) 
(4): Volume number 
SA: SA Law Reports 
11: Page or section number 
(N): In this case Natal - where the case was heard. Similarly, (C) woud indicate Cape, 
(G) Gauteng, and so on. 
NOTE: no . after the v 
OTHER REFERENCES (E.G. REPORTS) SHOULD FOLLOW THE SAME 
FORMAT: Author(s). Title. Publisher place: Publisher name, year; pages. 
Cited manuscripts that have been accepted but not yet published can be included as 
references followed by '(in press)'. 
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Unpublished observations and personal communications in the text must not appear 
in the reference list. The full name of the source person must be provided for personal 
communications e.g. '...(Prof. Michael Jones, personal communication)'. 
 
 
From submission to acceptance 
Submission and peer-review 
To submit an article: 
Please ensure that you have prepared your manuscript in line with 
the SAJCH requirements. 
All submissions should be submitted via Editorial Manager 
The following are required for your submission to be complete: 
Anonymous manuscript (unless otherwise stated) 
Author Agreement form [forthcoming] 
Manuscript 
Any supplementary files: figures, datasets, patient consent form, permissions for 
published images, etc. 
Once the submission has been successfully processed on Editorial Manager, it will 
undergo a technical check by the Editorial Office before it will be assigned to an editor 
who will handle the review process. If the author guidelines have not been 
appropriately followed, the manuscript may be sent back to the author for correcting. 
 
 
Peer Review Process 
 
All manuscripts are reviewed initially by the Editor-in-Chief and only those that meet 
the scientific and editorial standards of the journal, and fit within the aims and scope of 
the journal, will be sent for external peer review. Each manuscript is reviewed by either 
one or two reviewers selected on the basis of their expertise in the field. A double blind 
review process is followed at SAJCH. 
Authors are expected to receive feedback from reviewers and an editorial decision 
within approximately 6 weeks of submission. The time period of the entire review 
process may vary however depending upon the quality of the manuscript submitted, 
reviewers’ responses and the time taken by the authors to submit the revised 
manuscript. 
Manuscripts from review may be accepted, rejected or returned to the author for 
revision or resubmission for review. Authors will be directed to submit revised 
manuscripts within two months of receiving the editor’s decision, and are requested to 
submit a point by point response to the reviewers’ comments. Manuscripts which 
authors are requested to revise and resubmit will be sent for a second round of peer 
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review, often to the original set of reviewers. All final decisions on a manuscript are at 




An accepted manuscript is passed to a Managing Editor to assign to a copyeditor (CE). 
The CE copyedits in Word, working on house style, format, 
spelling/grammar/punctuation, sense and consistency, and preparation for typesetting. 
If the CE has an author queries, he/she will contact the corresponding author and send 
them the copyedited Word doc, asking them to solve the queries by means of track 
changes or comment boxes. 
The authors are typically asked to respond within 1-3 days. Any comments/changes 
must be clearly indicated e.g. by means of track changes. Do not work in the original 
manuscript - work in the copyedited file sent to you and make your changes clear. 
The CE will finalise the article and then it will be typeset. 
Once typeset, the CE will send a PDF of the file to the authors to complete their final 
check, while simultaneously sending to the 2nd-eye proofreader. 
The authors are typically asked to complete their final check and sign-off within 1-2 
days. No major additional changes can be accommodated at this point. 
The CE implements the authors’ and proofreader’s mark-ups, finalises the file, and 
prepares it for the upcoming issue. 
 
 
Changing contact details or authorship 
Please notify the Editorial Department of any contact detail changes, including email, 
to facilitate communication. 
 
 




Should you become aware of an error or inaccuracy in yours or someone else’s 
contribution after it has been published, please inform us as soon as possible via an 
email to publishing@hmpg.co.za,including the following details: 
Journal, volume and issue in which published 
Article title and authors 
Description of error and details of where it appears in the published article 
Full detail of proposed correction and rationale 
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We will investigate the issue and provide feedback. If appropriate, we will correct the 
web version immediately, and will publish anerratum in the next issue. All 
investigations will be conducted in accordance with guidelines provided by the 




Retraction of an article is the prerogative of either the original authors or the editorial 
team of HMPG. Should you wish to withdraw your article before publication, we need 
a signed statement from all the authors. 
 
 
Should you wish to retract your published article, all authors have to agree in writing 
before publication of the retraction. 
Send an email to publishing@hmpg.co.za, including the following details: 
Journal, volume and issue to which article was submitted/in which article was 
published 
Article title and authors 
Description of reason for withdrawal/retraction. 
 
 
We will make a decision on a case-by-case basis upon review by the editorial 
committee in line with international best practices. Comprehensive feedback will be 
communicated with the authors with regard to the process. In case where there is any 
suspected fraud or professional misconduct, we will follow due process as 








Published articles are covered by the following major indexing services. As such 
articles published in the SAJCH are immediately available to all users of these 













Contact claudian@hmpg.co.za for information on submitting ad hoc/commissioned 
supplements, including guidelines, conference/congress abstracts, Festschrifts, etc. 
 
 
Submission Preparation Checklist 
As part of the submission process, authors are required to check off their submission's 
compliance with all of the following items, and submissions may be returned to authors 
that do not adhere to these guidelines. 
Named authors consent to publication and meet the requirements of authorship as set 
out by the journal. 
The submission has not been previously published, nor is it before another journal for 
consideration. 
The text complies with the stylistic and bibliographic requirements in Author 
Guidelines. 
The manuscript is in Microsoft Word or RTF document format. The text is single- 
spaced, in 12-point Times New Roman font, and contains no unnecessary formatting. 
Illustrations/figures are high resolution/quality (not compressed) and in an acceptable 
format (preferably TIFF or PNG). These must be submitted as 'supplementary files' 
(not in the manuscript). 
For illustrations/figures or tables that have been published elsewhere, the author has 
obtained written consent to republication from the copyright holder. 
Where possible, references are accompanied by a digital object identifier (DOI) and 
PubMed ID (PMID)/PubMed Central ID (PMCID). 
An abstract has been included where applicable. 
The research was approved by a Research Ethics Committee (if applicable) 
Any conflict of interest (or competing interests) is indicated by the author(s). 
 
Copyright Notice 
Copyright of published material remains in the Authors’ name. This allows authors to 
use their work for their own non-commercial purposes without seeking permission from 




Authors are free to copy, print and distribute their articles, in full or in part, for teaching 
activities, and to deposit or include their work in their own personal or institutional 
database or on-line website. Authors are requested to inform the Journal/Publishers of 
their desire/intention to include their work in a thesis or dissertation or to republish their 
work in any derivative form (but not for commercial use). 
Material submitted for publication in the SAJCH is accepted provided it has not been 
published or submitted for publication elsewhere. Please inform the editorial team if 
the main findings of your paper have been presented at a conference and published 




The SAJCH is committed to protecting the privacy of the users of this journal website. 
The names, personal particulars and email addresses entered in this website will be 
used only for the stated purposes of this journal and will not be made available to third 
parties without the user’s permission or due process. Users consent to receive 
communication from the SAJCH for the stated purposes of the journal. Queries with 
regard to privacy may be directed to publishing@hmpg.co.za. 
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This is a prospective observational study nested in a cohort of preterm infants 
enrolled in a RCT to determine the efficacy of a RSV monoclonal antibody. The study 
enrolled 53 infants who had been followed up very closely for a year after premature 
birth between 29 - 35 wGA. The study describes the rate of illness episodes and 
hospitalisations in this group of children and explores associations between illness 
episodes and socioeconomic factors. 
 
 
The conclusion of the study, supported by the data, is that there are high rates of 
illness episodes and hospitalisation in this group of patients. 
 
 
This is a relevant article that describes not only the hospitalisation of premature 
children but also the illness episodes that did not require hospitalisation, which 
makes it more novel and informative. 
 
 
The article is well written and the results are mostly well presented. 
Thank  you  for  taking  the  time  to  review this manuscript. We appreciate the 
comments and made changes as explained below. 
There are two methodological issues with this study. The first being that HIV 
exposed children were excluded. This is unfortunate, but was a prerequisite of the 
parent study. The exclusion of these children should be highlighted in the abstract, 
the results and the conclusion, so that it does not seem that the results can be 
generalized to all children. 
This is an excellent suggestion. We have incorporated this suggestion throughout 
the manuscript. We have also included a short paragraph in the strengths and 
limitations section elaborating the potential effect on this sample of infants with 
reference to two large local studies. 
The second issue is much more important. The parent study was a study looking at 
the efficacy of a RSV monoclonal antibody. This was a randomized controlled trial. 
As previous literature on palivizumab and motavizumab have shown us, these 
treatments have a huge effect on the incidence of wheezing and hospitalisations in 
the first year of life. The fact that some of these children received a treatment that 
actively decreases illness episodes and hospitalisations in this exact group is a 
major flaw in this study and makes the reader wonder if the results are not an under- 
representation of the actual rates found in this subgroup. The fact that roughly half 
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the patients would have received the treatment and the other half did not means that 
we are dealing with two very different groups of patients, but describing them as a 
single unit. This problem needs to be addressed by the authors before i would 
consider this manuscript for publication. The results need to be presented as a whole 
group as well as divided into treatment and placebo groups. This would included the 
demographic data as well as the clinical data. If this is not possible, there should at 
a minimum be a very strongly worded admission and explanation regarding this 
issue, before a final decision can be reached on the acceptance of the manuscript. 
This is a valid point, which we reconsidered. This is a novel monoclonal antibody so 
the efficacy is unknown. However, we have included further references to highlight 
the point that Palivuzimab and Motavizumab decrease outpatient visits and 
admissions for RSV. This means that our study possibly underestimated the number 
of illness episodes and hospital admissions. We have amended the ‘methods’ and 
‘strengths and limitations’ sections to describe this more clearly. We are still blinded 
to intervention/placebo but even if we were not, the sample size would be too small 
to compare groups for our local study. 
 
 
Despite the risk of underestimating the number of infections and admission in the 
general population, we feel that this is still important information to be placed in the 
public domain. The message that there are a large number of infectious episodes 
(rarely reported) and admissions is important and the fact that this is probably an 
underestimation is we feel (now) well explained. 
Abstract: 
Background: Please change 'after discharge' to 'after initial discharge' 
We made the changes accordingly. 
Abstract: 
Objectives: Add HIV unexposed before 'preterm infants' 
We made the changes accordingly. 
Abstract: 
Objectives: Add risk before 'factors' in 'associated factors' 
We made the changes accordingly. 
Abstract: 
Results: Remove 'with one death' and add it add end of sentence 'of which 31 were 
hospital admissions' 
Instead of adding it to the end of the sentence, which may imply that this infant died 





Conclusion: Need to highlight that these findings were only in HIV unexposed 
children and can not be generalized to all children 
The first sentence in ‘conclusion’ was changed to ‘This is one of the few studies to 
record all illness episodes and not just admissions over a one-year period for HIV 
unexposed infants’. 
Introduction: 
Please change 'increasing and large' to 'large and increasing' 
We made the changes accordingly. 
Introduction: 
Accepted abbreviation is LMIC. If plural needed, then LMICs 
We noted this error and changed it to ‘LMIC’. 
Results: 
Page 5, line 37. There is to much repetition of results here. I would combine all these 
first 3 paragraphs into one as a quick summary and then refer to the table for more 
detail. 
We agree that most of the data is represented by the table and was repeated in 
writing. We have amalgamated three paragraphs into one. 
Results: 
Under infant characteristics, the first paragraph should be moved down this section, 
after the next paragraph. 
We moved the paragraph as suggested. 
Results: 
Not sure if figure 1 adds much more than the text and could be used as a 
supplementary table. 
Thank you for this suggestion. We compared the use of a graph and a table and feel 
that this graph represents the data easily in a strong visual way and that a table would 
not demonstrate the rapid decline in exclusive breast feeding over time as vividly as 
a graph. We are also within the guidelines of the number of tables and figures one 




Table 3: impetigo is misspelled 
We corrected the spelling error. 
Results: 
Table 5 in the text describes the actual Table 4. 
We have labeled the tables correctly. 
Discussion: 
In the discussion, please add a paragraph explaining how HIV infection and 
exposure may influence childhood health and the incidence of infections. Also, 
reiterate that this study only included HIV unexposed children and that the results 
cannot be generalized to the whole population. 
Thank you once again for pointing this out. We have made changes throughout the 
paper to draw attention to this important part of our study. In the ‘strengths and 
limitations’ section we added an extensive paragraph with two large South African 
studies, looking at the outcomes of HIV exposed and HIV unexposed infants. The 
findings of these two studies are noted in the changes to alert the reader that there 
is an effect on illness episodes in infants of HIV exposed mothers. This effect 
appears to be greatest in the first six months and then the effect is ameliorated. 
Conclusion: 
Mention only in HIV unexposed children. 
The opening sentence of the conclusion now reads ‘There are high rates of 
intercurrent infection and hospitalisation in HU preterm infants in their first year of 
life.’ with the addition of HU (HIV unexposed infants) as referenced in the strengths 
and limitations by Le Roux and Slogrove. 
 
